NASDAQ$OMER
Omeros Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Omeros reported first quarter 2022 financial results.
Omeros Corporation reported a net loss of $33.0 million for the first quarter of 2022. The company earned royalties of $13.8 million from Rayner's net sales of OMIDRIA. Omeros had $142.2 million in cash, cash equivalents and short-term investments as of March 31, 2022.
- Omeros earned $13.8 million in royalties from Rayner's OMIDRIA sales in Q1 2022.
- Net loss for the quarter was $33.0 million, or $0.53 per share.
- Omeros had $142.2 million in cash, cash equivalents, and short-term investments as of March 31, 2022.
- The company is pursuing formal dispute resolution with the FDA regarding narsoplimab approval.
Headline financials
Revenue & EPS history
Omeros · Revenue · Quarterly
$491K
Revenue by segment
Omeros · $31.9M total across 1 segment · Q4 2021
- OMIDRIA royalties$31.9M—100.0%
Forward guidance
Omeros anticipates value-creating events throughout the remainder of 2022.
Tailwinds
- OMS906 data in patients with paroxysmal nocturnal hemoglobinuria
- Data from our efforts in COVID-19
- Updates on our Phase 1 study evaluating our long-acting MASP-2 inhibitor OMS1029
- Completion of enrollment for the proteinuria endpoint in our narsoplimab ARTEMIS-IgAN trial
- Potential to earn an OMIDRIA-related $200-million commercial milestone payment
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+2.3%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+9.4%
Avg return
30 days after
42%
27 / 64 earnings
Positive
+64.2%
Q4 2019
Best reaction
-21.2%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -20.8% | — | |
| Q4 2025 | +7.5% | +3.1% | +42.6% | |
| Q3 2025 | +26.3% | +30.9% | +61.6% | |
| Q1 2025 | -18.7% | -21.3% | -13.9% | |
| Q4 2024 | -3.8% | -14.1% | -14.6% | |
| Q3 2024 | +63.1% | +39.0% | +79.1% | |
| Q2 2024 | -10.5% | -2.1% | -16.7% | |
| Q1 2024 | -21.2% | -21.4% | -3.3% | |
| Q4 2023 | -11.6% | -0.6% | -1.4% | |
| Q3 2023 | -3.8% | +14.6% | +97.7% | |
| Q2 2023 | -1.2% | -6.1% | -20.7% | |
| Q1 2023 | +21.2% | +14.2% | +51.4% | |
| Q4 2022 | +15.6% | +8.6% | +72.1% | |
| Q3 2022 | -16.9% | -10.9% | -35.6% | |
| Q2 2022 | +10.5% | +5.6% | -19.4% | |
| Q1 2022 | -5.4% | +15.9% | -22.5% | |
| Q4 2021 | -5.1% | -11.2% | -16.5% | |
| Q3 2021 | +7.6% | +10.1% | +6.3% | |
| Q2 2021 | +1.5% | +4.4% | +5.3% | |
| Q1 2021 | +3.8% | +2.5% | -9.6% | |
| Q4 2020 | +1.2% | -7.3% | -10.7% | |
| Q3 2020 | +6.1% | +11.3% | +37.0% | |
| Q2 2020 | +12.5% | -4.0% | -22.2% | |
| Q1 2020 | -6.2% | -12.0% | -2.2% | |
| Q4 2019 | +64.2% | +51.8% | +8.7% | |
| Q3 2019 | +2.2% | -3.9% | -3.9% | |
| Q2 2019 | +14.7% | +20.6% | +14.4% | |
| Q1 2019 | +5.1% | +0.9% | -8.3% | |
| Q4 2018 | +12.5% | +9.2% | +20.5% | |
| Q3 2018 | -20.3% | -22.2% | -14.2% | |
| Q2 2018 | -18.0% | -4.7% | +16.9% | |
| Q1 2018 | +18.0% | +45.0% | +8.7% | |
| Q4 2017 | -0.9% | -0.1% | +10.6% | |
| Q3 2017 | +27.5% | +33.1% | +37.5% | |
| Q2 2017 | +12.4% | +5.9% | -6.8% | |
| Q1 2017 | -7.7% | -6.4% | -4.7% | |
| Q4 2016 | -7.9% | -2.9% | +34.7% | |
| Q3 2016 | +28.7% | +45.8% | +9.4% | |
| Q2 2016 | +3.0% | -7.9% | -8.9% | |
| Q1 2016 | -15.0% | — | — | |
| Q4 2015 | +24.7% | — | — | |
| Q3 2015 | -1.3% | — | — | |
| Q2 2015 | -3.1% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +9.7% | — | — | |
| Q2 2014 | -5.7% | — | — | |
| Q1 2014 | -6.9% | — | — | |
| Q4 2013 | -11.7% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | -7.2% | — | — | |
| Q1 2013 | +17.5% | — | — | |
| Q4 2012 | -3.7% | — | — | |
| Q3 2012 | -17.1% | — | — | |
| Q2 2012 | -2.2% | — | — | |
| Q1 2012 | -0.6% | — | — | |
| Q4 2011 | -3.5% | — | — | |
| Q3 2011 | -2.0% | — | — | |
| Q2 2011 | +3.0% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -3.8% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q2 2010 | -12.3% | — | — | |
| Q1 2010 | -3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro